Literature DB >> 17457175

Trauma-related infections in battlefield casualties from Iraq.

Kyle Petersen1, Mark S Riddle, Janine R Danko, David L Blazes, Richard Hayden, Sybil A Tasker, James R Dunne.   

Abstract

OBJECTIVE: To describe risks for, and microbiology and antimicrobial resistance patterns of, war trauma associated infections from Operation Iraqi Freedom.
BACKGROUND: : The invasion of Iraq resulted in casualties from high-velocity gunshot, shrapnel, and blunt trauma injuries as well as burns. Infectious complications of these unique war trauma injuries have not been described since the 1970s.
METHODS: Retrospective record review of all trauma casualties 5 to 65 years of age evacuated from the Iraqi theatre to U.S. Navy hospital ship, USNS Comfort, March to May 2003.War trauma-associated infection was defined by positive culture from a wound or sterile body fluid (ie, blood, cerebrospinal fluid) and at least two of the following infection-associated signs/symptoms: fever, dehiscence, foul smell, peri-wound erythema, hypotension, and leukocytosis. A comparison of mechanisms of injury, demographics, and clinical variables was done using multivariate analysis.
RESULTS: Of 211 patients, 56 met criteria for infection. Infections were more common in blast injuries, soft tissue injuries, >3 wound sites, loss of limb, abdominal trauma, and higher Injury Severity Score (ISS). Wound infections accounted for 84% of cases, followed by bloodstream infections (38%). Infected were more likely to have had fever prior to arrival, and had higher probability of ICU admission and more surgical procedures. Acinetobacter species (36%) were the predominant organisms followed by Escherichia coli and Pseudomonas species (14% each).
CONCLUSIONS: Similar to the Vietnam War experience, gram-negative rods, particularly Acinetobacter species, accounted for the majority of wound infections cared for on USNS Comfort during Operation Iraqi Freedom. Multidrug resistance was common, with the exception of the carbapenem class, limiting antibiotic therapy options.

Entities:  

Mesh:

Year:  2007        PMID: 17457175      PMCID: PMC1877069          DOI: 10.1097/01.sla.0000251707.32332.c1

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  [Surveillance of bacterial causes of hospital infections during periods of war and peace].

Authors:  Vesna Suljagić; Veljko Mirović; Branka Tomanović
Journal:  Vojnosanit Pregl       Date:  2003 Jul-Aug       Impact factor: 0.168

2.  The bacteriology of open wounds.

Authors:  R RUSTIGIAN; A CIPRIANI
Journal:  J Am Med Assoc       Date:  1947-01-25

3.  Bacterial flora of one hundred and twelve combat wounds.

Authors:  J J Kovaric; T Matsumoto; A S Dobek; H F Hamit
Journal:  Mil Med       Date:  1968-08       Impact factor: 1.437

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Hospital-acquired infections following the 1999 Marmara earthquake.

Authors:  O Oncül; O Keskin; H V Acar; Y Küçükardali; R Evrenkaya; E M Atasoyu; C Top; S Nalbant; S Ozkan; G Emekdaş; S Cavuşlu; M H Us; A Pahsa; M Gökben
Journal:  J Hosp Infect       Date:  2002-05       Impact factor: 3.926

6.  Septic complications of war wounds.

Authors:  M J Tong
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

7.  Combat surgery in communication zone. I. War wound and bacteriology (preliminary report).

Authors:  T Matsumoto; S R Wyte; R V Moseley; R J Hawley; G R Lackey
Journal:  Mil Med       Date:  1969-09       Impact factor: 1.437

8.  Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).

Authors:  Robert P Rennie; Ronald N Jones; Alan H Mutnick
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

9.  Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002.

Authors:  Katherine M Campbell; Andrew F Vaughn; Kevin L Russell; Besa Smith; Dinice L Jimenez; Christopher P Barrozo; John R Minarcik; Nancy F Crum; Margaret A K Ryan
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

10.  Community-acquired methicillin-resistant Staphylococcus aureus among military recruits.

Authors:  Craig E Zinderman; Byron Conner; Mark A Malakooti; James E LaMar; Adam Armstrong; Bruce K Bohnker
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

View more
  59 in total

Review 1.  Infection in conflict wounded.

Authors:  W G P Eardley; K V Brown; T J Bonner; A D Green; J C Clasper
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

2.  War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli.

Authors:  Patrick McGann; Erik Snesrud; Ana C Ong; Lakshmi Appalla; Michael Koren; Yoon I Kwak; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

3.  A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.

Authors:  Madeline R Galac; Erik Snesrud; Francois Lebreton; Jason Stam; Michael Julius; Ana C Ong; Rosslyn Maybank; Anthony R Jones; Yoon I Kwak; Kate Hinkle; Paige E Waterman; Emil P Lesho; Jason W Bennett; Patrick Mc Gann
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Infectious Complications After Deployment Trauma: Following Wounded US Military Personnel Into Veterans Affairs Care.

Authors:  Jay R McDonald; Stephen Y Liang; Ping Li; Salwa Maalouf; Clinton K Murray; Amy C Weintrob; Elizabeth R Schnaubelt; Janis Kuhn; Anuradha Ganesan; William Bradley; David R Tribble
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

5.  Morphine, but not trauma, sensitizes to systemic Acinetobacter baumannii infection.

Authors:  Jessica M Breslow; M Alexandra Monroy; John M Daly; Joseph J Meissler; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 6.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection.

Authors:  Cheryl Y M Okumura; Andrew Hollands; Dan N Tran; Joshua Olson; Samira Dahesh; Maren von Köckritz-Blickwede; Wdee Thienphrapa; Courtney Corle; Seung Nam Jeung; Anna Kotsakis; Robert A Shalwitz; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2012-02-28       Impact factor: 4.599

8.  Impact of Operational Theater on Combat and Noncombat Trauma-Related Infections.

Authors:  David R Tribble; Ping Li; Tyler E Warkentien; Bradley A Lloyd; Elizabeth R Schnaubelt; Anuradha Ganesan; William Bradley; Deepak Aggarwal; M Leigh Carson; Amy C Weintrob; Clinton K Murray
Journal:  Mil Med       Date:  2016-10       Impact factor: 1.437

9.  Synthetic molecular evolution of host cell-compatible, antimicrobial peptides effective against drug-resistant, biofilm-forming bacteria.

Authors:  Charles G Starr; Jenisha Ghimire; Shantanu Guha; Joseph P Hoffmann; Yihui Wang; Leisheng Sun; Brooke N Landreneau; Zachary D Kolansky; Isabella M Kilanowski-Doroh; Mimi C Sammarco; Lisa A Morici; William C Wimley
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-02       Impact factor: 11.205

Review 10.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.